International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 831-838 , 1 November 2007

Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme

  • Judith M. Ford, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • Corresponding Author InformationReprint requests to: Judith M. Ford, M.D., Ph.D., c/o Anne Wagner, Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, 200 UCLA Medical Plaza, Suite B265, Los Angeles, CA 90095-6951. Tel: (310) 825-6577; Fax: (310) 794-9795
    • ,
  • Wendy Seiferheld, M.S.

      Affiliations

    • Radiation Therapy Oncology Group Statistical Unit, Philadelphia, PA
    • ,
  • Jeffrey R. Alger, Ph.D.

      Affiliations

    • Department of Radiology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • ,
  • Genevieve Wu, Ph.D.

      Affiliations

    • Department of Radiology, University of California, Los Angeles, School of Medicine, Los Angeles, CA
    • ,
  • Thyra J. Endicott, M.D.

      Affiliations

    • Department of Radiation Oncology, Torrance Memorial Medical Center, Torrance, CA
    • ,
  • Minesh Mehta, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Wisconsin School of Medicine, Madison, WI
    • ,
  • Walter Curran, M.D., F.A.C.R.

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
    • ,
  • See-Chun Phan, M.D.

      Affiliations

    • Pharmacyclics Inc., Sunnyvale, CA

Received 2 August 2006 ,Revised 4 April 2007 ,Accepted 13 April 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Research supported by the National Cancer Institute Cancer Therapy Evaluation Program (Grant RO3 CA 78170); National Institutes of Health supplement to UCLA Johnson Comprehensive Cancer Center Core grant; National Institutes of Health General Clinical Research Center, UCLA (Grant M01-RR00865), General Clinical Research Centers Program; and Pharmacyclics Inc. Comparative analysis supported by the Radiation Therapy Oncology Group (Grants U10 CA21661, CCOP U10 CA37422), and Stat U10 CA32115 from the National Cancer Institute.

 The contents of this manuscript are the sole responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

 Conflict of interest: S.-C. Phan is employed by, and owns stock in, Pharmacyclics, Inc.; J. Ford, M. Mehta, J. Alger, and G. Wu have each received research funding from Pharmacyclics, Inc.; W. Seiferheld, T. Endicott, and W. Curran have no conflicts of interest.

PII: S0360-3016(07)00680-3

doi: 10.1016/j.ijrobp.2007.04.017

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 3 , Pages 831-838 , 1 November 2007

Article Tools

* Image Usage & Resolution